The Madison Heights City Council on Friday voted to reverse its decision to deny a drag performer from reading books to ...

A Harvard oncologist’s measured presentation of trial data on May 31 drew an extended standing ovation from hundreds of ...

Founded by Ed Blackburn and his family following his battle with 9/11-related pancreatic cancer in 2019, the Blackburn Family ...

The vopimetostat + daraxonrasib Phase 1/2 readout shows a 92% objective response rate (11/12) and 90% progression-free ...

We are celebrating that breakthrough at the precise moment Washington is taking apart the research base behind it.

Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month ...

New research shows a novel pill is helping people with advanced pancreatic cancer live longer. It's not a cure, as the drug's ...

A two-drug combination exhibited durable clinical benefit as second- or third-line treatment for pancreatic cancer, according to a topline data announcement released by one of the agent’s ...

An international phase 3 clinical trial has found that an investigational oral medication (a daily pill) doubled the median ...

A new research paper was published in Volume 17 of Oncotarget on June 3, 2026, titled "The anticancer effects of PCAIs in ...

TORONTO — Oncologists say they're working to quickly get Canadian patients with pancreatic cancer into clinical trials for a ...

Enthusiasm is growing for daraxonrasib, a new pancreatic cancer drug showing unprecedented results in clinical trials by ...